<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">CHLORAL HYDRATE</span><br/>(klor'al hye'drate)<br/><span class="topboxtradename">Aquachloral Supprettes, </span><span class="topboxtradename">Noctec, </span><span class="topboxtradename">Novochlorhydrate <img border="0" src="../images/maple.gif"/><br/></span><b>Classifications:</b> <span class="classification">central nervous system agent</span>; <span class="classification">anxiolytic, sedative-hypnotic</span><br/><b>Prototype: </b>Secobarbital<br/><b>Pregnancy Category: </b>C<br/><b>Controlled Substance: </b>Schedule IV<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>500 mg capsules; 250 mg/5 mL, 500 mg/5 mL syrup; 324 mg, 500 mg, 648 mg suppositories</p>
<h1><a name="action">Actions</a></h1>
<p>Produces "physiologic sleep" by mild cerebral depression with little effect on respirations or BP and little or no
         hangover.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Chloral hydrate is a sedative-hypnotic which does not affect sleep physiology (e.g., REM sleep) in low doses. Has little or
         no analgesic action.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Short-term management of insomnia, for general sedation (especially in the young and the older adult), for sedation before
         and after surgery, to reduce anxiety associated with drug withdrawal, and alone or with paraldehyde to prevent or suppress
         alcohol withdrawal symptoms.
      </p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Known hypersensitivity to chloral hydrate or chloral derivatives; severe hepatic, renal, or cardiac disease; rectal dosage
         form in patients with proctitis; oral use in patients with esophagitis, gastritis, gastric or duodenal ulcers; pregnancy (category
         C), lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>History of intermittent porphyria, asthma, history of or proneness to drug dependence, depression, suicidal tendencies.</p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Sedative</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/PR</span> 250 mg t.i.d. p.c.<br/><span class="rdage">Child:</span> <span class="rdroute">PO/PR</span> 2550 mg/kg/d divided q68h (max: 500 mg/dose)<br/><br/><span class="indicationtitle">Hypnotic</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO/PR</span> 500 mg1 g 1530 min before h.s. or 30 min before surgery<br/><span class="rdage">Geriatric:</span> <span class="rdroute">PO/PR</span> 250 mg h.s.<br/><span class="rdage">Child:</span> <span class="rdroute">PO/PR</span> 50 mg/kg 1530 min before h.s. or 30 min before surgery (max: 1 g)<br/><br/><span class="indicationtitle">EEG Premedication</span><br/><span class="rdage">Child:</span> <span class="rdroute">PO/PR</span> 2025 mg/kg 3060 min prior to procedure<br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Dilute liquid preparations in chilled fluids to minimize unpleasant taste.</li>
<li>Watch to see that drug is not cheeked and hoarded.</li>
</ul><span class="adminroutetype">Rectal</span><br/><ul>
<li>Moisten suppository with a water-based lubricant, such as K-Y jelly, prior to insertion.</li>
<li>Solutions are preserved in tightly covered, light-resistant containers.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span>
<span class="speceff-life">Angioedema</span>, eosinophilia, breath odor, leukopenia, ketonuria, renal and hepatic damage, <span class="speceff-life">sudden death</span>. <span class="typehead">CV:</span> Arrhythmias, <span class="speceff-life">cardiac arrest</span>. <span class="typehead">GI:</span>
<span class="speceff-common">Nausea, vomiting, diarrhea,</span> severe gastritis. <span class="typehead">CNS:</span> Dizziness, motor incoordination, headache. <span class="typehead">Skin:</span> Purpura, urticaria, erythematous rash, eczema, erythema multiforme, fixed drug eruptions. <span class="typehead">Special Senses:</span> Conjunctivitis. 
      <h1><a name="dtintefer">Diagnostic Test Interference</a></h1>
<p>False-positive results for <span class="alt">urine glucose</span> with <span class="alt">Benedict's solutions,</span> and possibly with <span class="alt">Clinitest</span> but not with <span class="alt">glucose oxidase methods</span> (e.g., <span class="alt">Clinistix,</span>
<span class="alt">Diastix,</span>
<span class="alt">TesTape</span>). Possible interference with fluorometric test for <span class="alt">urine catecholamines</span> (if chloral hydrate is administered within 48 h of test) and <span class="alt">urinary 17-OHCS</span> determinations (by modification of <span class="alt">Reddy,</span>
<span class="alt">Jenkins,</span>
<span class="alt">Thorn procedure</span>).
      </p>
<h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span>
<b>Alcohol,</b>
<span class="classification">barbiturates</span>, <b>paraldehyde,</b> other <span class="classification">cns depressants</span> potentiate CNS depression; tachycardia may also occur with <b>alcohol</b>; increases anticoagulant effect of <span class="classification">oral anticoagulants</span>; <b>furosemide</b> IV can produce flushing, diaphoresis, BP changes. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Readily absorbed from oral or rectal administration. <span class="typehead">Onset:</span> 3060 min. <span class="typehead">Peak:</span> 13 h. <span class="typehead">Duration:</span> 48 h. <span class="typehead">Distribution:</span> Well distributed to all tissues; 7080% protein bound; crosses placenta. <span class="typehead">Metabolism:</span> Metabolized in liver to the active metabolite trichloroethanol. <span class="typehead">Elimination:</span> Excreted primarily by kidneys, with a small amount excreted in feces via bile. <span class="typehead">Half-Life:</span> 811 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Chloral hydrate is not intended for relief of pain. When used in the presence of pain, it may cause excitement and delirium.</li>
<li>Do not discontinue abruptly following prolonged use. Sudden withdrawal from dependent patients may produce delirium, mania,
            or convulsions.
         </li>
<li>Monitor for S&amp;S of allergic skin reactions, which may occur within several hours or as long as 10 d after drug administration.</li>
<li>Evaluate patient's response to chloral hydrate and continued need for the drug.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Do not ambulate without assistance until response to drug is known.</li>
<li>Avoid concomitant use of alcoholic beverages.</li>
<li>Avoid driving and other potentially hazardous activities while under the influence of chloral hydrate.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>